EWTX — Edgewise Therapeutics, Inc. stock price, charts and financials

Latest market price

43.71

+0.19+0.44%

Overview Short InterestFilings

EWTXQT84Edgewise Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

43.71+0.44%

Loading chart...

Signal & projected range

Earnings big miss — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

MANE-5.44%$108.17 DNTH-0.78%$108.08 CELC-1.08%$91.78 DYN+0.23%$26.31 ACAD+0.27%$29.29 DFTX-4.71%$43.97 ELVN-1.26%$59.70 CRSP+1.04%$54.08

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	107.59M	Perf Week	13.24%

Market Cap	4.68B	Forward P/E	-	EPS next Y	-1.73	Insider Trans	-0.54%	Shs Float	79.59M	Perf Month	-9.99%

Enterprise Value	4.61B	PEG	1.35	EPS next Q	-	Inst Own	115.16%	Short Float	12.66%	Perf Quarter	22.32%

Income	-197.13M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	6.87	Perf Half Y	60.06%

Sales	0.00	P/B	10.46	EPS next Y	14.22%	ROA	-41.11%	Short Interest	10.07M	Perf YTD	75.34%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-39.01%	52W High	48.61 -10.08%	Perf Year	221.89%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-48.46%	52W Low	12.35 253.82%	Perf 3Y	544.74%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	5.65% 5.91%	Perf 5Y	148.54%

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-14.48%	Oper. Margin	0.00%	ATR (14)	2.57	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	16.24	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	56.73	Recom	2.18

Dividend Gr. 3/5Y	-	Current Ratio	16.24	EPS Q/Q	-6.98%	SMA20	6.94%	Beta	0.32	Target Price	49.09

Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	-	SMA50	10.82%	Rel Volume	1.01	Prev Close	43.52

Employees	154	LT Debt/Eq	0.01	Earnings	Nov 05	SMA200	43.08%	Avg Volume	1.40M	Price	43.71

IPO Date	Mar 26, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.08% -	Net Debt/EBITDA	0.35	Volume	1,407,229	Change	0.44%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-20-26	Reiterated	Evercore ISI Group	Outperform	$45 → $55
Jul-09-26	Initiated	Oppenheimer	Outperform	$51
Jul-06-26	Reiterated	Guggenheim	Buy	$51
Jun-17-26	Reiterated	RBC Capital	Outperform	$48 → $59
Jun-17-26	Reiterated	Goldman Sachs	Neutral	$20 → $32
Jun-16-26	Reiterated	Leerink Partners		$50 → $52
Jun-02-26	Reiterated	HC Wainwright & Co.	Buy	$45
Jun-02-26	Reiterated	RBC Capital	Outperform	$42 → $48
Jun-01-26	Reiterated	Raymond James		$52 → $66
May-06-26	Reiterated	Truist Financial	Buy	$46 → $52

Latest News

Aug-06-26

Aug-06-2608:45AM

Edgewise Therapeutics Q2 EPS $(0.53) Misses $(0.47) EstimateBenzinga

08:00AM

Edgewise Therapeutics Reports Second Quarter 2026 Financial Resultsprnewswire.com

Jul-20-26

Jul-20-2608:57AM

Evercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $55Benzinga

Jul-13-26

Jul-13-2608:30AM

Servier finalise l'acquisition de l'activité dystrophie musculaire d'Edgewise Therapeuticsprnewswire.com

08:30AM

Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipelineprnewswire.com

Jul-09-26

Jul-09-2609:32AM

Oppenheimer Initiates Coverage On Edgewise Therapeutics with Outperform Rating, Announces Price Target of $51Benzinga

Jul-06-26

Jul-06-2610:09AM

Guggenheim Maintains Buy on Edgewise Therapeutics, Raises Price Target to $51Benzinga

Jul-01-26

Jul-01-2608:00AM

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rulesprnewswire.com

Jun-18-26

Jun-18-2610:31AM

Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For ThursdayBenzinga

Jun-17-26

Jun-17-2611:02AM

RBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $59Benzinga

09:05AM

Delta Air Lines To Rally Around 12%? Here Are 10 Top Analyst Forecasts For WednesdayBenzinga

08:20AM

Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $32Benzinga

06:22AM

Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy TranscriptSeekingAlpha

03:43AM

Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy - SlideshowSeekingAlpha

Jun-16-26

Jun-16-2601:40PM

Edgewise Therapeutics Reports Improvements In Heart Drug TrialBenzinga

Company

Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.

Ownership

Total institutional ownership115.16%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019
Total Revenue	0	0	0	—	—	—	—
Cost of Goods Sold Incl. D&A	2	0	0	—	—	—	—
Gross Profit	-2	0	0	—	—	—	—
Selling, General and Administrative Excl. Other	40	32	23	—	—	—	—
Research and Development	151	127	91	—	—	—	—
Other Operating Expense	-2	0	0	—	—	—	—
Operating Income	-191	-159	-114	—	—	—	—
Interest Expense	0	0	0	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—
Non-Operating Income (Expense)	24	25	14	—	—	—	—
Net Income Before Taxes	-168	-134	-100	—	—	—	—
Income Taxes	0	0	0	—	—	—	—
Consolidated Net Income	-168	-134	-100	—	—	—	—
Net Income From Continuing Operations	-168	-134	-100	—	—	—	—
Net Income	-168	-134	-100	—	—	—	—
EPS (Recurring)	-1.63	-1.45	-1.57	—	—	—	—
EPS (Basic, Before Extraordinaries)	-1.63	-1.45	-1.57	—	—	—	—
EPS (Diluted)	-1.63	-1.45	-1.57	—	—	—	—
EBITDA	-166	-132	-98	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—
Shares Outstanding	103	92	64	—	—	—	—
Market Capitalization	2,556	2,456	700	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Russell Alan J	Chief Scientific Officer	Jul 01 '26	Option Exercise	0.36	200,000	71,195	224,555	Jul 02
Russell Alan J	Chief Scientific Officer	Jul 01 '26	Sale	39.41	200,000	7,881,402	24,555	Jul 02
Donovan Joanne M.	CMO	May 05 '26	Option Exercise	7.08	50,000	354,000	54,367	May 05
Donovan Joanne M.	CMO	May 05 '26	Sale	38.57	50,000	1,928,400	4,367	May 05
Donovan Joanne M.	CMO	May 04 '26	Sale	31.29	5,230	163,663	4,367	May 05
Donovan Joanne M.	CMO	Apr 01 '26	Option Exercise	7.08	28,662	202,927	38,259	Apr 02
Donovan Joanne M.	CMO	Apr 01 '26	Sale	32.31	28,662	926,095	9,597	Apr 02
Donovan Joanne M.	CMO	Mar 31 '26	Option Exercise	7.08	21,338	151,073	30,935	Mar 31
Donovan Joanne M.	CMO	Mar 31 '26	Sale	32.12	21,338	685,308	9,597	Mar 31
Donovan Joanne M.	CMO	Mar 27 '26	Sale	30.98	16,358	506,734	9,597	Mar 30
Edris Badreddin	Director	Jan 21 '26	Option Exercise	1.47	115,471	170,265	135,291	Jan 23
Edris Badreddin	Director	Jan 21 '26	Sale	29.44	115,471	3,399,467	19,820	Jan 23
Russell Alan J	Chief Scientific Officer	Nov 12 '25	Option Exercise	0.18	100,000	18,000	123,400	Nov 13
Russell Alan J	Chief Scientific Officer	Nov 12 '25	Sale	21.12	100,000	2,112,450	23,400	Nov 13
Fox Jonathan C	Director	Nov 11 '25	Buy	18.64	10,700	199,403	23,702	Nov 13

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.